Ravulizumab failed to show a statistically significant improvement in event‑free survival for patients with thrombotic microangiopathy after hematopoietic stem cell transplantation, according to the topline results of the phase 3 ALXN1210‑TMA‑313 trial.
Trial design and primary outcome
The global, double‑blind, placebo‑controlled study enrolled 146 participants aged 12 years or older across 18 countries. All subjects had developed HSCT‑TMA within 12 months of transplant and continued to show signs of the disorder for at least three days after initial management.
After an open‑label lead‑in to confirm dosing, patients were randomized 1:1 to receive intravenous ravulizumab or placebo, each alongside best supportive care, for a 26‑week period. The primary endpoint measured event‑free survival, defined as the time from randomization until TMA‑related clinical worsening or death.
Related: User Blocked from Online Access
Investigators observed a trend toward benefit, but the difference did not reach statistical significance. Detailed efficacy and safety data have not yet been disclosed, and the sponsor plans to present full results at a future medical meeting.
Safety profile and secondary measures
The safety observations reported were consistent with the known profile of ravulizumab and with complications typical of stem‑cell transplant patients. Specific rates for adverse events, infections, or treatment discontinuations were not released.
No new safety signals emerged.
Secondary endpoints included overall survival, non‑relapse mortality, and various measures of TMA response, but these results were omitted from the initial announcement.
Related: User access denied after system block
HSCT‑TMA is a rare, severe complication characterized by endothelial injury and microvascular clot formation, which can damage kidneys, the heart, the gastrointestinal tract, and other organs. Clinical signs often overlap with other post‑transplant issues, making early diagnosis difficult. Complement overactivation is thought to play a role, and several therapies target different points in the pathway.
Ravulizumab, a long‑acting monoclonal antibody that blocks complement protein C5, is already approved for conditions such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. It is not yet approved for HSCT‑TMA, and the trial’s outcome may influence future regulatory discussions.
For clinicians, the current findings reinforce the need to weigh existing supportive care options against experimental therapies, especially as real‑world evidence accumulates. The ongoing dialogue with regulatory authorities will likely shape future trial designs and potential label extensions for ravulizumab.
